$646 Million is the total value of Rock Springs Capital Management LP's 83 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DHR | New | DANAHER CORP DEL | $6,458,000 | – | 85,000 | +100.0% | 1.00% | – |
| CTLT | New | CATALENT INC | $5,031,000 | – | 201,000 | +100.0% | 0.78% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $4,891,000 | – | 20,500 | +100.0% | 0.76% | – |
| ZSPH | New | ZS PHARMA INC | $3,609,000 | – | 92,000 | +100.0% | 0.56% | – |
| EPZM | New | EPIZYME INC | $3,551,000 | – | 131,000 | +100.0% | 0.55% | – |
| JAZZ | New | JAZZ PHARMACEUTICALS PLC | $2,930,000 | – | 18,250 | +100.0% | 0.45% | – |
| ROKA | New | ROKA BIOSCIENCE INC | $2,513,000 | – | 250,000 | +100.0% | 0.39% | – |
| PFNX | New | PFENEX INC | $2,392,000 | – | 325,000 | +100.0% | 0.37% | – |
| KITE | New | KITE PHARMA INC | $2,351,000 | – | 82,474 | +100.0% | 0.36% | – |
| AERI | New | AERIE PHARMACEUTICALS INC | $2,055,000 | – | 99,300 | +100.0% | 0.32% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $2,052,000 | – | 300,000 | +100.0% | 0.32% | – |
| RCPT | New | RECEPTOS INC | $1,397,000 | – | 22,500 | +100.0% | 0.22% | – |
| XNPT | New | XENOPORT INC | $785,000 | – | 146,000 | +100.0% | 0.12% | – |
| HRTX | New | HERON THERAPEUTICS INC | $583,000 | – | 70,000 | +100.0% | 0.09% | – |
| AAVL | New | AVALANCHE BIOTECHNOLOGIES IN | $246,000 | – | 7,198 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 43 | Q2 2024 | 4.0% |
| NEUROCRINE BIOSCIENCES INC | 42 | Q2 2024 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 42 | Q2 2024 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 42 | Q2 2024 | 2.4% |
| ACADIA HEALTHCARE COMPANY IN | 41 | Q2 2024 | 4.4% |
| ASCENDIS PHARMA A/S | 38 | Q2 2024 | 1.3% |
| BIOMARIN PHARMACEUTICAL INC | 38 | Q2 2024 | 1.3% |
| MACROGENICS INC | 38 | Q2 2024 | 0.5% |
| AMICUS THERAPEUTICS INC | 37 | Q2 2024 | 0.6% |
| ADAPTIMMUNE THERAPEUTICS PLC | 37 | Q2 2024 | 1.2% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Travere Therapeutics, Inc. | May 01, 2024 | 4,411,983 | 5.8% |
| Xilio Therapeutics, Inc. | April 05, 2024 | 3,003,259 | 8.7% |
| Aclaris Therapeutics, Inc. | February 14, 2024 | 2,998,495 | 4.2% |
| AGIOS PHARMACEUTICALS, INC. | February 14, 2024 | 2,152,173 | 3.8% |
| Gamida Cell Ltd.Sold out | February 14, 2024 | 0 | 0.0% |
| Immunocore Holdings plc | February 14, 2024 | 2,661,507 | 5.4% |
| Inozyme Pharma, Inc. | February 14, 2024 | 3,681,174 | 6.0% |
| Mereo BioPharma Group plc | February 14, 2024 | 39,919,255 | 5.7% |
| SPRUCE BIOSCIENCES, INC. | February 14, 2024 | 2,609,125 | 6.4% |
| Spyre Therapeutics, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.